Shots:
- Welcome to the 2025 series of Know Your Investor, featuring top venture capital firms focused on healthcare.
- This edition highlights Janus Henderson Group Plc, a global investment firm managing approximately $378.7B in assets across Equities, Fixed Income, Multi-Asset, and Alternatives.
- In 2024, the firm invested $5.36B across six funding rounds, adding 39 healthcare and biotech companies to its portfolio. For the complete report, reach out to us at connect@pharmashots.com
Formed through the 2017 merger of Janus Capital Group and Henderson Global Investors, Janus Henderson Group Plc has grown into a global investment powerhouse. It offers a comprehensive range of investment products and solutions for institutional and retail investors, managing assets across four key capabilities: Equities, Fixed Income, Multi-Asset, and Alternatives.
In 2024, Janus Henderson participated in six funding rounds, including PIPE, Series A–D, Series F, and beyond. Key additions to its portfolio include:
- ProfoundBio
- PepGen
- Entrada Therapeutics
- Solid Biosciences
The largest investment was a $400M PIPE round in Avidity Biosciences.
Janus Henderson’s healthcare investment strategy emphasizes small and mid-cap biotech companies addressing high unmet medical needs with cost-effective and innovative solutions.
The firm’s three-pronged approach includes:
- Identifying promising scientific and commercial opportunities.
- Prioritizing small/mid-cap biotech.
- Mitigating risk using its proprietary value-at-risk framework.
It expands its healthcare portfolio primarily through the Global Life Sciences Fund and Horizon Biotechnology Fund.
Therapeutic Areas of Focus:
- Oncology
- Cardiovascular diseases
- Dermatology
- Endocrine and metabolic disorders
- Hematology
- Infectious diseases
- Musculoskeletal disorders
- Neurology
- Ophthalmology
- Renal diseases
Technological Focus:
- Antibodies
- Small molecules
- Cell and gene therapies
In 2024:
- Invested in 39 companies
- 60% of investments were through PIPE
- 17.5% were through Series A and B
Key Investments in 2024:
- $400M PIPE - Avidity Biosciences
- $350M PIPE - Crinetics Pharmaceuticals
- $250M PIPE - Olema Oncology
Quarterly Investments in 2024:
- Q1: 15 investments worth $2.48B
- Q2: 8 investments worth $0.84B
- Q3: 4 investments worth $0.64B
- Q4: 13 investments worth $1.4B
The table below depicts the top 5 out of the 40 investments made by Janus Henderson Group Plc:
Note: (For a complete report, reach out to us at connect@pharmashots.com with the subject line “Janus Henderson” or for early access to complete data for future reports and analysis, register here: https://forms.office.com/r/VwFu6aUm80)
Related Post: Know Your Investor: Perceptive Advisors (March’25 Edition)
